 | ||||||||||||||||
| ||||||||||||||||
| ||||||||||||||||
|
Home :
Research :
Equity Research :
U.S. Equity Research :
U.S. Equity Research News
U.S. Equity Research News
Zhang Downgrades OSI Pharmaceuticals (OSIP) to MARKET PERFORM from OUTPERFORM March 2, 2010 Jason Zhang, PhD, senior research analyst covering Biotechnology, has today downgraded OSI Pharmaceuticals (OSIP) to a MARKET PERFORM rating from OUTPERFORM. From Zhang's note: "After the announcement of Astellas' cash tender offer of OSIP shares at $52 per share, OSIP shares traded to above the offering price, suggesting that investors are hoping 1) that there may be a 'white knight' to bid even higher, or 2) Astellas may come back with a sweetener." To receive a full copy of the report or for more information, please contact your BMO Capital Markets representative. << Previous
Full List of News Items
|
|
Quick LinksPublications
|
|||||||||||||
|
||||||||||||||||
